Natera (NASDAQ:NTRA) CEO Sells $570,473.10 in Stock

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 2,190 shares of Natera stock in a transaction on Monday, July 27th. The shares were sold at an average price of $260.49, for a total value of $570,473.10. Following the transaction, the chief executive officer owned 106,553 shares in the company, valued at approximately $27,755,990.97. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

Get Natera alerts:

• On Tuesday, July 28th, Steven Leonard Chapman sold 3,580 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $909,570.60.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72.
• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $185,956.32.

Natera Stock Down 0.7%

NASDAQ:NTRA opened at $267.76 on Friday. The business’s 50-day moving average price is $246.77 and its 200 day moving average price is $222.22. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $288.04. The firm has a market cap of $38.35 billion, a P/E ratio of -164.27 and a beta of 1.51.

Institutional Trading of Natera

A number of hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after buying an additional 1,225,420 shares during the period. Wellington Management Group LLP raised its holdings in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. State Street Corp raised its holdings in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after acquiring an additional 72,087 shares during the period. Coatue Management LLC lifted its position in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Natera by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock valued at $596,078,000 after acquiring an additional 11,689 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. UBS Group set a $260.00 target price on shares of Natera in a research note on Wednesday, June 24th. Wells Fargo & Company lifted their price target on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Royal Bank Of Canada began coverage on Natera in a report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target on the stock. BTIG Research set a $275.00 price objective on Natera and gave the company a “buy” rating in a research report on Wednesday, June 24th. Finally, Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Read Our Latest Stock Analysis on Natera

About Natera

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More

• Five stocks we like better than Natera
• Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
• Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
• Apple’s Record Quarter Could Not Outrun Its Guidance Problem
• McKesson’s Compounding Keeps Adding Up

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.